Entering text into the input field will update the search result below

Equillium up 9% on advancement of itolizumab for COVID-19

Sep. 15, 2020 9:13 AM ETEquillium, Inc. (EQ) StockEQBy: Douglas W. House, SA News Editor1 Comment
  • Equillium (NASDAQ:EQ) has completed a pre-IND meeting with the FDA during which they discussed clinical development plans for itolizumab (EQ001) for the potential treatment of hospitalized COVID-19 patients.
  • The company expects to finalize the protocol for a Phase 3 study and submit its IND application next month. The randomized, double-blind, placebo-controlled clinical trial should launch in Q4.
  • It has begun applying to government agencies for funding support.
  • Shares up 9% premarket on modest volume.

Recommended For You

About EQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EQ--
Equillium, Inc.